抗血小板药-话题@MedSci

#抗血小板药#

48篇内容 | 953人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2032574, encodeId=b96320325e48d, content=<a href='/topic/show?id=e00855e5387' target=_blank style='color:#2F92EE;'>#抗血小板药#</a>, objectTitle=常用抗血小板药物不耐受、反应性低？这些治疗策略要掌握！, objectType=article, longId=737170, objectId=d02de371705d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d02de371705d, replyNumber=0, likeNumber=37, createdTime=2023-06-13, rootId=0, userName=shizhenshan, userId=ccbd84, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d02de371705d, moduleTitle=常用抗血小板药物不耐受、反应性低？这些治疗策略要掌握！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d02de371705d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2032572, encodeId=800d20325e251, content=<a href='/topic/show?id=e00855e5387' target=_blank style='color:#2F92EE;'>#抗血小板药#</a>, objectTitle=双联抗血小板药物多立维®在华上市，进一步提升ACS患者用药依从性, objectType=article, longId=727521, objectId=51cae2752113, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=51cae2752113, replyNumber=0, likeNumber=35, createdTime=2023-02-16, rootId=0, userName=shizhenshan, userId=ccbd84, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=51cae2752113, moduleTitle=双联抗血小板药物多立维®在华上市，进一步提升ACS患者用药依从性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=51cae2752113)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2032570, encodeId=15ee20325e00f, content=<a href='/topic/show?id=e00855e5387' target=_blank style='color:#2F92EE;'>#抗血小板药#</a>, objectTitle=临床笔记 | 抗血小板药物和抗凝药物相关性脑出血, objectType=article, longId=220426, objectId=226f2204265c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=226f2204265c, replyNumber=0, likeNumber=35, createdTime=2022-10-17, rootId=0, userName=shizhenshan, userId=ccbd84, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=226f2204265c, moduleTitle=临床笔记 | 抗血小板药物和抗凝药物相关性脑出血, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=226f2204265c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2032573, encodeId=256120325e37b, content=<a href='/topic/show?id=e00855e5387' target=_blank style='color:#2F92EE;'>#抗血小板药#</a>, objectTitle=阿司匹林、氯吡格雷、替格瑞洛…..抗血小板药物最全总结！, objectType=article, longId=728552, objectId=6aa3e2855286, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6aa3e2855286, replyNumber=0, likeNumber=40, createdTime=2023-02-12, rootId=0, userName=shizhenshan, userId=ccbd84, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6aa3e2855286, moduleTitle=阿司匹林、氯吡格雷、替格瑞洛…..抗血小板药物最全总结！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6aa3e2855286)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2032571, encodeId=de8d20325e159, content=<a href='/topic/show?id=e00855e5387' target=_blank style='color:#2F92EE;'>#抗血小板药#</a>, objectTitle=阿司匹林、氯吡格雷、替格瑞洛…..抗血小板药物全面总结！, objectType=article, longId=292052, objectId=e05b29205282, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e05b29205282, replyNumber=0, likeNumber=59, createdTime=2022-05-20, rootId=0, userName=shizhenshan, userId=ccbd84, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e05b29205282, moduleTitle=阿司匹林、氯吡格雷、替格瑞洛…..抗血小板药物全面总结！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e05b29205282)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2032569, encodeId=fd9b203256906, content=<a href='/topic/show?id=e00855e5387' target=_blank style='color:#2F92EE;'>#抗血小板药#</a>, objectTitle=抗凝联合抗血小板药物有消化道出血怎么停药？, objectType=article, longId=212428, objectId=5b022124289c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5b022124289c, replyNumber=0, likeNumber=38, createdTime=2022-01-16, rootId=0, userName=shizhenshan, userId=ccbd84, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5b022124289c, moduleTitle=抗凝联合抗血小板药物有消化道出血怎么停药？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5b022124289c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2032568, encodeId=4a0020325686d, content=<a href='/topic/show?id=e00855e5387' target=_blank style='color:#2F92EE;'>#抗血小板药#</a>, objectTitle=JAMA：CYP2C19Lof携带患者与基因型指导的抗血小板药物治疗策略, objectType=article, longId=199944, objectId=236e199944ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=236e199944ce, replyNumber=0, likeNumber=47, createdTime=2020-12-25, rootId=0, userName=shizhenshan, userId=ccbd84, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=236e199944ce, moduleTitle=JAMA：CYP2C19Lof携带患者与基因型指导的抗血小板药物治疗策略, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=236e199944ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2032567, encodeId=a9e9203256e0a, content=<a href='/topic/show?id=e00855e5387' target=_blank style='color:#2F92EE;'>#抗血小板药#</a>, objectTitle=Lancet:70岁以上非ST升高急性冠状动脉综合征患者抗血小板药物选择, objectType=article, longId=193080, objectId=d1ed19308063, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d1ed19308063, replyNumber=0, likeNumber=37, createdTime=2021-03-01, rootId=0, userName=shizhenshan, userId=ccbd84, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d1ed19308063, moduleTitle=Lancet:70岁以上非ST升高急性冠状动脉综合征患者抗血小板药物选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d1ed19308063)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2032566, encodeId=efa72032566ce, content=<a href='/topic/show?id=e00855e5387' target=_blank style='color:#2F92EE;'>#抗血小板药#</a>, objectTitle=Clinical Translational Gastroenterology：接受双重抗血小板药物治疗的患者行冷圈套息肉切除术后并发症风险, objectType=article, longId=184575, objectId=fa2f1845e502, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fa2f1845e502, replyNumber=0, likeNumber=32, createdTime=2020-10-30, rootId=0, userName=shizhenshan, userId=ccbd84, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fa2f1845e502, moduleTitle=Clinical Translational Gastroenterology：接受双重抗血小板药物治疗的患者行冷圈套息肉切除术后并发症风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fa2f1845e502)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2032562, encodeId=951a2032562e9, content=<a href='/topic/show?id=e00855e5387' target=_blank style='color:#2F92EE;'>#抗血小板药#</a>, objectTitle=【ESC 2019】中国心脏病和中风患者中，仅11%应用他汀，18.3%用抗血小板药物, objectType=article, longId=178650, objectId=a2541e8650b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a2541e8650b4, replyNumber=0, likeNumber=29, createdTime=2019-09-10, rootId=0, userName=shizhenshan, userId=ccbd84, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a2541e8650b4, moduleTitle=【ESC 2019】中国心脏病和中风患者中，仅11%应用他汀，18.3%用抗血小板药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a2541e8650b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2032565, encodeId=5ce420325653d, content=<a href='/topic/show?id=e00855e5387' target=_blank style='color:#2F92EE;'>#抗血小板药#</a>, objectTitle=中国六成房颤患者仍应用抗血小板药物！胡大一等报告中国房颤注册研究：仅32%使用抗凝药物, objectType=article, longId=184180, objectId=23f5184180c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=23f5184180c8, replyNumber=0, likeNumber=41, createdTime=2019-12-31, rootId=0, userName=shizhenshan, userId=ccbd84, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=23f5184180c8, moduleTitle=中国六成房颤患者仍应用抗血小板药物！胡大一等报告中国房颤注册研究：仅32%使用抗凝药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=23f5184180c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2032561, encodeId=34792032561ef, content=<a href='/topic/show?id=e00855e5387' target=_blank style='color:#2F92EE;'>#抗血小板药#</a>, objectTitle=JACC：双重抗血小板药物治疗对冠脉支架植入术后缺血风险的影响, objectType=article, longId=160642, objectId=48ff16064275, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=48ff16064275, replyNumber=0, likeNumber=43, createdTime=2020-01-10, rootId=0, userName=shizhenshan, userId=ccbd84, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=48ff16064275, moduleTitle=JACC：双重抗血小板药物治疗对冠脉支架植入术后缺血风险的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=48ff16064275)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2032563, encodeId=fcbd20325634d, content=<a href='/topic/show?id=e00855e5387' target=_blank style='color:#2F92EE;'>#抗血小板药#</a>, objectTitle=中国心脏病和中风患者中，抗血小板药物和他汀等二级预防药物的应用不太理想, objectType=article, longId=178682, objectId=6b851e8682f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6b851e8682f9, replyNumber=0, likeNumber=36, createdTime=2019-10-14, rootId=0, userName=shizhenshan, userId=ccbd84, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6b851e8682f9, moduleTitle=中国心脏病和中风患者中，抗血小板药物和他汀等二级预防药物的应用不太理想, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6b851e8682f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2032564, encodeId=4e9f2032564cd, content=<a href='/topic/show?id=e00855e5387' target=_blank style='color:#2F92EE;'>#抗血小板药#</a>, objectTitle=AP&T：抗凝血剂和/或抗血小板药使用者胃肠道出血后再出血的概率, objectType=article, longId=179087, objectId=f4da1e9087b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f4da1e9087b0, replyNumber=0, likeNumber=30, createdTime=2019-09-28, rootId=0, userName=shizhenshan, userId=ccbd84, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f4da1e9087b0, moduleTitle=AP&T：抗凝血剂和/或抗血小板药使用者胃肠道出血后再出血的概率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f4da1e9087b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2032560, encodeId=4e2a20325606d, content=<a href='/topic/show?id=e00855e5387' target=_blank style='color:#2F92EE;'>#抗血小板药#</a>, objectTitle=安贞医院1204 例冠脉支架血栓病例报告：绝大多数患者在接受规范抗血小板药物治疗, objectType=article, longId=152385, objectId=9f58152385cb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9f58152385cb, replyNumber=0, likeNumber=29, createdTime=2018-11-19, rootId=0, userName=shizhenshan, userId=ccbd84, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9f58152385cb, moduleTitle=安贞医院1204 例冠脉支架血栓病例报告：绝大多数患者在接受规范抗血小板药物治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9f58152385cb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2032559, encodeId=e7c4203255908, content=<a href='/topic/show?id=e00855e5387' target=_blank style='color:#2F92EE;'>#抗血小板药#</a>, objectTitle=Health Technol Assess:预防急性缺血性卒中或TIA后卒中复发抗血小板药物越多越好？, objectType=article, longId=149860, objectId=b99e1498607b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b99e1498607b, replyNumber=0, likeNumber=44, createdTime=2018-12-21, rootId=0, userName=shizhenshan, userId=ccbd84, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b99e1498607b, moduleTitle=Health Technol Assess:预防急性缺血性卒中或TIA后卒中复发抗血小板药物越多越好？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b99e1498607b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2032558, encodeId=298d20325582d, content=<a href='/topic/show?id=e00855e5387' target=_blank style='color:#2F92EE;'>#抗血小板药#</a>, objectTitle=Health Technol Assess：预防急性缺血性卒中或TIA后卒中复发抗血小板药物越多越好？, objectType=article, longId=149776, objectId=0bf6149e7653, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0bf6149e7653, replyNumber=0, likeNumber=38, createdTime=2019-07-16, rootId=0, userName=shizhenshan, userId=ccbd84, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0bf6149e7653, moduleTitle=Health Technol Assess：预防急性缺血性卒中或TIA后卒中复发抗血小板药物越多越好？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0bf6149e7653)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2032555, encodeId=f979203255575, content=<a href='/topic/show?id=e00855e5387' target=_blank style='color:#2F92EE;'>#抗血小板药#</a>, objectTitle=Heart：新型抗血小板药物预防复发性心肌梗死的效果分析！, objectType=article, longId=132450, objectId=37121324500e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=37121324500e, replyNumber=0, likeNumber=37, createdTime=2018-05-01, rootId=0, userName=shizhenshan, userId=ccbd84, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=37121324500e, moduleTitle=Heart：新型抗血小板药物预防复发性心肌梗死的效果分析！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=37121324500e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2032557, encodeId=9157203255e3e, content=<a href='/topic/show?id=e00855e5387' target=_blank style='color:#2F92EE;'>#抗血小板药#</a>, objectTitle=JAMA：抗血小板药物治疗导致的出血风险研究, objectType=article, longId=141779, objectId=fb5a141e79f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fb5a141e79f4, replyNumber=0, likeNumber=35, createdTime=2019-03-10, rootId=0, userName=shizhenshan, userId=ccbd84, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fb5a141e79f4, moduleTitle=JAMA：抗血小板药物治疗导致的出血风险研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fb5a141e79f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2032556, encodeId=851420325564d, content=<a href='/topic/show?id=e00855e5387' target=_blank style='color:#2F92EE;'>#抗血小板药#</a>, objectTitle=ACC 2018：PHARMCLO研究：抗血小板药物的精准治疗年代来临了吗？, objectType=article, longId=132456, objectId=1c5e1324564c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c5e1324564c, replyNumber=0, likeNumber=38, createdTime=2019-01-21, rootId=0, userName=shizhenshan, userId=ccbd84, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c5e1324564c, moduleTitle=ACC 2018：PHARMCLO研究：抗血小板药物的精准治疗年代来临了吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c5e1324564c)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

抗血小板药

2020-05-29

shizhenshan (审核中...)

前往app查看评论内容

#抗血小板药#

常用抗血小板药物不耐受、反应性低？这些治疗策略要掌握！

2023-06-13

shizhenshan (审核中...)

前往app查看评论内容

#抗血小板药#

双联抗血小板药物多立维®在华上市，进一步提升ACS患者用药依从性

2023-02-16

shizhenshan (审核中...)

前往app查看评论内容

#抗血小板药#

临床笔记 | 抗血小板药物和抗凝药物相关性脑出血

2022-10-17

shizhenshan (审核中...)

前往app查看评论内容

#抗血小板药#

阿司匹林、氯吡格雷、替格瑞洛…..抗血小板药物最全总结！

2023-02-12

shizhenshan (审核中...)

前往app查看评论内容

#抗血小板药#

阿司匹林、氯吡格雷、替格瑞洛…..抗血小板药物全面总结！

2022-05-20

shizhenshan (审核中...)

前往app查看评论内容

#抗血小板药#

抗凝联合抗血小板药物有消化道出血怎么停药？

2022-01-16

shizhenshan (审核中...)

前往app查看评论内容

#抗血小板药#

JAMA：CYP2C19Lof携带患者与基因型指导的抗血小板药物治疗策略

2020-12-25

shizhenshan (审核中...)

前往app查看评论内容

#抗血小板药#

Lancet:70岁以上非ST升高急性冠状动脉综合征患者抗血小板药物选择

2021-03-01

shizhenshan (审核中...)

前往app查看评论内容

#抗血小板药#

Clinical Translational Gastroenterology：接受双重抗血小板药物治疗的患者行冷圈套息肉切除术后并发症风险

2020-10-30

shizhenshan (审核中...)

前往app查看评论内容

#抗血小板药#

【ESC 2019】中国心脏病和中风患者中，仅11%应用他汀，18.3%用抗血小板药物

2019-09-10

shizhenshan (审核中...)

前往app查看评论内容

#抗血小板药#

中国六成房颤患者仍应用抗血小板药物！胡大一等报告中国房颤注册研究：仅32%使用抗凝药物

2019-12-31

shizhenshan (审核中...)

前往app查看评论内容

#抗血小板药#

JACC：双重抗血小板药物治疗对冠脉支架植入术后缺血风险的影响

2020-01-10

shizhenshan (审核中...)

前往app查看评论内容

#抗血小板药#

中国心脏病和中风患者中，抗血小板药物和他汀等二级预防药物的应用不太理想

2019-10-14

shizhenshan (审核中...)

前往app查看评论内容

#抗血小板药#

AP&T：抗凝血剂和/或抗血小板药使用者胃肠道出血后再出血的概率

2019-09-28

shizhenshan (审核中...)

前往app查看评论内容

#抗血小板药#

安贞医院1204 例冠脉支架血栓病例报告：绝大多数患者在接受规范抗血小板药物治疗

2018-11-19

shizhenshan (审核中...)

前往app查看评论内容

#抗血小板药#

Health Technol Assess:预防急性缺血性卒中或TIA后卒中复发抗血小板药物越多越好？

2018-12-21

shizhenshan (审核中...)

前往app查看评论内容

#抗血小板药#

Health Technol Assess：预防急性缺血性卒中或TIA后卒中复发抗血小板药物越多越好？

2019-07-16

shizhenshan (审核中...)

前往app查看评论内容

#抗血小板药#

Heart：新型抗血小板药物预防复发性心肌梗死的效果分析！

2018-05-01

shizhenshan (审核中...)

前往app查看评论内容

#抗血小板药#

JAMA：抗血小板药物治疗导致的出血风险研究

2019-03-10

shizhenshan (审核中...)

前往app查看评论内容

#抗血小板药#

ACC 2018：PHARMCLO研究：抗血小板药物的精准治疗年代来临了吗？

2019-01-21

科室
- - 订阅+
  - 更多科室
工具
服务